Afficher la notice abrégée

dc.rights.licenseopenen_US
dc.contributor.authorHOUNKONNOU, Cornelia P. A.
dc.contributor.authorNDAM, Nicaise Tuikue
dc.contributor.authorFIEVET, Nadine
dc.contributor.authorACCROMBESSI, Manfred
dc.contributor.authorYOVO, Emmanuel
dc.contributor.authorMAMA, Atikatou
dc.contributor.authorSOSSOU, Darius
dc.contributor.authorVIANOU, Bertin
dc.contributor.authorMASSOUGBODJI, Achille
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBRIAND, Valerie
dc.contributor.authorCOT, Michel
dc.contributor.authorCOTTRELL, Gilles
dc.date.accessioned2022-02-14T08:54:53Z
dc.date.available2022-02-14T08:54:53Z
dc.date.issued2021-12-01
dc.identifier.issn1537-6591 (Electronic) 1058-4838 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/124717
dc.description.abstractEnBACKGROUND: Harmful maternal and neonatal health outcomes result from malaria in pregnancy, the prevention of which primarily relies on intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP). The World Health Organization recommends IPTp-SP in sub-Saharan Africa, but implementation is highly heterogeneous and often suboptimal in terms of the number of doses and their timing. In this study, we assessed the impact of this heterogeneity on malaria in pregnancy, mainly with respect to submicroscopic Plasmodium falciparum infections. METHODS: We used data from 273 Beninese women followed throughout pregnancy. Screening for P. falciparum infections, using both microscopy-based and polymerase chain reaction (PCR)-based methods, was performed monthly, and information on IPTp-SP doses was collected. Gestational age was estimated by repeated ultrasound scans. Using a negative binomial model, we investigated the effect of IPTp-SP doses and timing after 17 weeks of gestation on the number of P. falciparum infections, focusing on submicroscopic infections detectable only by PCR. RESULTS: At least 2 IPTp-SP doses were taken by 77.3% of the women. The median gestational age at the first IPTp-SP dose was 22 weeks. A late first IPTp-SP dose (>21.2 weeks) was marginally associated with an increased number of P. falciparum infections (adjusted incidence rate ratio [aIRR] = 1.3; P = .098). The number of IPTp-SP doses was not associated with the number of submicroscopic infections (aIRR = 1.2, P = .543). CONCLUSIONS: A late first IPTp-SP dose failed to provide optimal protection against P. falciparum, especially submicroscopic infections. This highlights the need for a new antimalarial drug for IPTp that could be taken early in pregnancy.
dc.description.sponsorshipImpact du paludisme précoce au cours de la grossesse sur la croissance fœtale au Bénin - ANR-13-JSV1-0004en_US
dc.language.isoENen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subject.enSubmicroscopic P. falciparum infection
dc.subject.enPregnancy
dc.subject.enIntermittent preventive treatment
dc.subject.enProspective cohort
dc.subject.enSub-Saharan Africa
dc.title.enSuboptimal Intermittent Preventive Treatment in Pregnancy (IPTp) is Associated With an Increased Risk of Submicroscopic Plasmodium falciparum Infection in Pregnant Women: A Prospective Cohort Study in Benin
dc.typeArticle de revueen_US
dc.identifier.doi10.1093/cid/ciaa1355en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed32901806en_US
bordeaux.journalClinical Infectious Diseasesen_US
bordeaux.pagee3759-e3767en_US
bordeaux.volume73en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue11en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamIDLICen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.identifier.funderIDAgence Nationale de la Rechercheen_US
bordeaux.identifier.funderIDFondation de Franceen_US
hal.identifierhal-03173206
hal.version1
hal.exportfalse
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Clinical%20Infectious%20Diseases&rft.date=2021-12-01&rft.volume=73&rft.issue=11&rft.spage=e3759-e3767&rft.epage=e3759-e3767&rft.eissn=1537-6591%20(Electronic)%201058-4838%20(Linking)&rft.issn=1537-6591%20(Electronic)%201058-4838%20(Linking)&rft.au=HOUNKONNOU,%20Cornelia%20P.%20A.&NDAM,%20Nicaise%20Tuikue&FIEVET,%20Nadine&ACCROMBESSI,%20Manfred&YOVO,%20Emmanuel&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée